A BET inhibitor, iBET726, suppresses PD-L1 in addition to MHC class I and cancels the immunotherapy effect in a melanoma model [65], suggesting a possible disadvantage of the BET inhibitor in an anti-tumor immune response to melanoma. Here, DNER is linked to neoplasm.